Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117304 · Präparat HOS-094569
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 5094–5135 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117305 · Präparat HOS-094569
Hypersensitivity reactions, including cases of rash (including urticaria), anaphylactic reactions, and
angioneurotic oedema have been reported (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage de8af9fa2e259930dc59b95768020a3d9f2ea0267bfff5ec3c7dde614bf402c3 · Zeichen 5137–5298 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117306 · Präparat HOS-094569
SCARs including SJS and TEN, which can be life-threatening or fatal, have been reported in
association with epoetin treatment (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage b1062500c6e29f69ec7ba2f2997caef4b0da2798d7bd01b99619e059af8338d3 · Zeichen 5300–5444 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117307 · Präparat HOS-094569
Hypertensive crisis with encephalopathy and seizures, requiring the immediate attention of a physician
and intensive medical care, have occurred also during epoetin alfa treatment in patients with
previously normal or low blood pressure. Particular attention should be paid to sudden stabbing
migraine-like headaches as a possible warning signal (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage 1165112b6086e48e2fdce5265637230b4020bb35828a1dd317f7df1bc9b9ef2e · Zeichen 5446–5810 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117308 · Präparat HOS-094569
Antibody-mediated pure red cell aplasia has been very rarely reported in < 1/10 000 cases per patient
year after months to years of treatment with epoetin alfa (see section 4.4). More cases have been
reported with subcutaneous route of administration, compared with the intravenous route.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage 2ae2e331292ced10fc5c499195d7f24148d69e381f25ad838dcb6c06a3918b5f · Zeichen 5812–6100 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117309 · Präparat HOS-094569
Adult patients with low- or intermediate-1-risk MDS
In the randomised, double-blind, placebo-controlled, multicentre study 4 (4.7%) subjects experienced
TVEs (sudden death, ischaemic stroke, embolism, and phlebitis). All TVEs occurred in the epoetin
alfa group and in the first 24 weeks of the study. Three were confirmed TVE and in the remaining case
(sudden death), the thromboembolic event was not confirmed. Two subjects had significant risk
factors (atrial fibrillation, heart failure and thrombophlebitis).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage 820779ce29896446aef44fd466de2252bd8b49205deba5008c32de25ef9f9a8a · Zeichen 6102–6614 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117310 · Präparat HOS-094569
Paediatric population with chronic renal failure on haemodialysis
The exposure of paediatric patients with chronic renal failure on haemodialysis in clinical studies and
post-marketing experience is limited. No paediatric-specific adverse reactions not mentioned
previously in the table above, or any that were not consistent with the underlying disease were
reported in this population.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage 3c60f192c41bf906a0996f4b7bef2fc060451087f62a2db57a33b91563a59a7c · Zeichen 6616–7003 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117311 · Präparat HOS-094569
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 7005–7045 im Abschnitt
Nebenwirkungen · Epoetin Alfa Hexal
Epoetin alfa HEXAL 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 2 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 10 000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa HEXAL 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117312 · Präparat HOS-094569
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T12:53:00Z · SHA-256 601fb2973d7e0801e2f137c3ceb16c47233d34d04a9f0a0082b20983c4550a9e · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 7047–7361 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.